Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris
19/12/2019 - 09:22 | PortfolioRead all news
Hamburg, 18 December 2019.
Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, today announced that the first patient has been enrolled in a first-in-human Phase 1 trial evaluating TPM203 in patients with pemphigus vulgaris (PV), an orphan autoimmune disease. TPM203 is Topas’ most advanced program and the first one from the Company’s proprietary Topas Particle Conjugates (TPC) platform technology to enter the clinic.